Gynaecological cancers, primarily cervical, ovarian, and uterine cancer, continue to be a significant threat to women's health worldwide.

While surgery and chemotherapy are the current standard treatment, patients often face challenges including high recurrence rates, severe side effects, and poor prognoses.

Therefore, there is an urgent need to identify effective targeted treatment approaches.

Antibody-Drug Conjugates (ADCs) have emerged as potent anti-tumour agents, leading to breakthroughs in the treatment of diverse solid tumours, including cervical and ovarian cancer.

Research on the topic is published in Science China Life Sciences.

Currently, two ADCs have been approved by the FDA for gynaecological cancer.

ADCs consist of three components: an antibody, a payload, and a linker.

They work by using the targeted antibody to deliver the cytotoxic payload directly into cancer cells.

Once inside, the drug is released, destroying the tumour cell from within while minimising damage to healthy cells.

The accelerated approval of the first ADC, tisotumab vedotin, for recurrent or metastatic cervical cancer in 2021 marked a new era in the treatment of gynaecological malignancies.

Since then, global research has accelerated, with numerous ADC drugs now in clinical trials for various gynaecological cancers.

Antigens of ADCs in gynaecological cancer include FRα，HER2, TF, Trop2, mesothelin, B7-H4, CDH-6, NaPi2b, and others.

The ADCs under clinical and preclinical investigation offering new prospects for patients who have exhausted traditional treatment options.

Experts note that while ADCs come with their own unique profile of side effects that need careful management, they will become more personalised and precise in the future, bringing further hope to patients.

Source: Science China Press